These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 8903861)

  • 1. Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations.
    Hutchison AJ; Were AJ; Boulton HF; Mawer EB; Laing I; Gokal R
    Nephron; 1996; 72(1):52-8. PubMed ID: 8903861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia.
    Hutchison AJ; Freemont AJ; Boulton HF; Gokal R
    Nephrol Dial Transplant; 1992; 7(12):1219-25. PubMed ID: 1337163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
    Weinreich T; Ritz E; Passlick-Deetjen J
    Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders.
    Parsons V; Baldwin D; Moniz C; Marsden J; Ball E; Rifkin I
    Nephron; 1993; 63(4):379-83. PubMed ID: 8459870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk/benefit in prophylaxis and treatment of secondary hyperparathyroidism. A comparison of two low calcium peritoneal dialysis fluids.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996; 11 Suppl 3():47-9. PubMed ID: 8840312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients.
    McIntyre CW; Patel V; Taylor GS; Fluck RJ
    Nephrol Dial Transplant; 2002 Sep; 17(9):1643-8. PubMed ID: 12198217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alkalosis and hypomagnesaemia: unwanted effects of a low-calcium CAPD solution.
    Tattersall JE; Dick C; Doyle S; Greenwood RN; Farrington K
    Nephrol Dial Transplant; 1995; 10(2):258-62. PubMed ID: 7753461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
    Sawyer N; Noonan K; Altmann P; Marsh F; Cunningham J
    Nephrol Dial Transplant; 1989; 4(2):105-9. PubMed ID: 2496350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
    Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC
    Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
    Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
    Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Replacement of aluminum-containing phosphate binders by calcium and magnesium carbonates in long-term hemodialysis].
    Zellweger U; Zaugg PY; Dambacher M; Binswanger U; Gautschi K; Hany A
    Dtsch Med Wochenschr; 1989 Apr; 114(17):659-64. PubMed ID: 2707134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure.
    Williams B; Vennegoor M; O'Nunan T; Walls J
    Nephrol Dial Transplant; 1989; 4(8):725-9. PubMed ID: 2510082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
    Brandi L; Nielsen PK; Bro S; Daugaard H; Olgaard K
    J Intern Med; 1998 Aug; 244(2):121-31. PubMed ID: 10095798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.
    O'Donovan R; Baldwin D; Hammer M; Moniz C; Parsons V
    Lancet; 1986 Apr; 1(8486):880-2. PubMed ID: 2870354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol.
    Cunningham J; Beer J; Coldwell RD; Noonan K; Sawyer N; Makin HL
    Nephrol Dial Transplant; 1992; 7(1):63-8. PubMed ID: 1316583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
    Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
    Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low calcium (1.25 mmol/L) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover.
    Shigematsu T; Kawaguchi Y; Kubo H; Nakayama M; Kato N; Yamamoto H; Osaka N; Hayakawa H; Ogawa A; Sakai O
    Adv Perit Dial; 1996; 12():250-6. PubMed ID: 8865914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium kinetic studies in patients on CAPD: improvement of secondary hyperparathyroidism without concomitant improvement of calcium turnover.
    Kurz P; Tsobanelis T; Brunkhorst R; Roth P; Werner E; Schoeppe W; Vlachojannis J
    Perit Dial Int; 1997; 17(1):59-65. PubMed ID: 9068024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.